Abstract
TU‐EF‐304‐11: Therapeutic Benefits of Collimation in Spot Scanning Proton Therapy in the Treatment of Brain Cancer
Medical physics (Lancaster), Vol.42(6Part33), pp.3617-3617
06/2015
DOI: 10.1118/1.4925666
Abstract
Purpose:
A dynamic collimation system (DCS) based on two orthogonal pairs of mobile trimmer blades has recently been proposed to reduce the lateral penumbra in spot scanning proton therapy (SSPT). The purpose of this work is to quantify the therapeutic benefit of using the DCS for SSPT of brain cancer by comparing un‐collimated and collimated treatment plans.
Methods:
Un‐collimated and collimated brain treatment plans were created for five patients, previously treated with SSPT, using an in‐house treatment planning system capable of modeling collimated and un‐collimated beamlets. Un‐collimated plans reproduced the clinically delivered plans in terms of target coverage and organ‐at‐risk (OAR) sparing, whereas collimated plans were re‐optimized to improve the organ‐at‐risk sparing while maintaining target coverage. Physical and biological comparison metrics such as dose distribution conformity, mean and maximum doses, normal tissue complication probability (NTCP) and risk of secondary brain cancer were used to evaluate the plans.
Results:
The DCS systematically improved the dose distribution conformity while preserving the target coverage. The average reduction of the mean dose to the 10‐mm ring surrounding the target and the healthy brain were 7.1% (95% CI: 4.2%–9.9%; p<0.01) and 14.3% (95% CI: 7.8%–20.8%; p<0.01), respectively. This yielded an average reduction of 12.0% (95% CI: 8.2%–15.7%; p<0.01) for the brain necrosis NTCP using the Flickinger model, and 14.2% (95% CI: 7.7%–20.8%; p<0.01) for the risk of secondary brain cancer. The average maximum dose reductions for the brainstem, chiasm, optic nerves, cochleae and pituitary gland when comparing un‐collimated and collimated plans were 14.3%, 10.4%, 11.2%, 13.0%, 12.9% and 3.4%, respectively. Evaluating individual plans using the Lyman‐Kutcher‐Burman NTCP model also yielded improvements.
Conclusion:
The lateral penumbra reduction performed by the DCS increases the normal tissue sparing capabilities of SSPT for brain tumor treatment while preserving the target coverage.
This research was financially supported by Ion Beam Applications S.A. (IBA, Louvain‐La‐Neuve, Belgium).
Details
- Title: Subtitle
- TU‐EF‐304‐11: Therapeutic Benefits of Collimation in Spot Scanning Proton Therapy in the Treatment of Brain Cancer
- Creators
- A MoignierE GeloverD WangR FlynnM KirkL LinT SolbergA LinD Hyer
- Resource Type
- Abstract
- Publication Details
- Medical physics (Lancaster), Vol.42(6Part33), pp.3617-3617
- Publisher
- American Association of Physicists in Medicine
- DOI
- 10.1118/1.4925666
- ISSN
- 0094-2405
- eISSN
- 2473-4209
- Number of pages
- 1
- Language
- English
- Date published
- 06/2015
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Radiation Oncology
- Record Identifier
- 9984047671702771
Metrics
8 Record Views